Rain Oncology Overview
Valuation check: RAIN's PEG ratio is -3.76, below the Healthcare sector average of 1.26.
Get informed when a big investor buys or sells
+ Follow-3.76
The PEG ratio measures a stock's valuation relative to its earnings growth rate. A PEG ratio below 1.0 may indicate that the stock is undervalued relative to its growth potential.
The latest PEG ratio for RAIN is -3.76. That is below the Healthcare sector average of 1.26. Investors often review this figure alongside Rain Oncology's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, RAIN currently prints -3.76 for PEG ratio, while the sector average sits near 1.26. That is roughly 399.4% below the sector mean. Large gaps often invite a closer look at Rain Oncology's growth, margins, and balance sheet.
A PEG ratio of -3.76 for Rain Oncology is not 'good' or 'bad' on its own. Compare it with the peer average (1.26) and with RAIN's multi-year chart on this page. Persistently elevated multiples need growth or quality to justify them; depressed multiples need a catalyst or evidence the business is misunderstood.
After noting RAIN's PEG ratio (-3.76), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Rain Oncology's PEG ratio against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
